Sava Technologies has successfully secured $19 million in a Series A financing round to propel the advancement of its wearable biosensor technology. The funding, led by Balderton Capital and Pentland Ventures, with participation from new investors Norrsken VC and JamJar Investments, along with several others, boosts the company’s total backing to $32 million. This financial injection will be pivotal in expediting regulatory approvals, enhancing commercialization efforts, expanding the workforce, and refining manufacturing capabilities at Sava’s London headquarters.
At the core of Sava’s innovation is a cutting-edge multi-molecule biosensor designed to detect biomarkers beneath the skin in real-time. The company’s initial product, a pain-free continuous glucose monitor (CGM), has exhibited promising early clinical results by providing seamless molecular insights directly to the user’s smartphone. The recent clinical trial conducted in the UK with 50 patients suffering from type 1 and insulin-dependent type 2 diabetes showcased accurate glucose readings for up to 10 days of continuous wear, surpassing the performance of many existing microsensor systems.
Sava envisions its biosensor technology extending beyond glucose tracking to potentially detect various other molecules, presenting a versatile platform for biomarker monitoring across diverse medical domains. Co-founder and co-CEO, Rafaël Michali, expressed optimism about the technology’s potential to revolutionize biosensing and personalized healthcare, offering a non-invasive and cost-effective alternative to conventional filament-based systems. The company’s modular platform, as highlighted by co-founder and co-CEO Renato Circi, signifies a paradigm shift towards real-time molecular health monitoring, promising a future where biosensors can empower individuals to track their health proactively.
The successful outcomes of Sava’s recent clinical trial are laying a strong foundation for forthcoming regulatory submissions and a significant study planned for the upcoming year. By leveraging its multi-analyte sensing platform, Sava aims to position itself as a frontrunner in biosensing technology, catering not only to chronic disease management but also to a wide array of health-related objectives. The company’s commitment to driving innovation in personalized healthcare underscores its ambition to redefine how individuals engage with their health on a molecular level, setting a new standard in the biosensor industry.
Key Takeaways:
– Sava Technologies secures $19 million in funding to advance its revolutionary biosensor technology for real-time molecular health monitoring.
– The company’s innovative multi-molecule biosensor, highlighted by a pain-free continuous glucose monitor, shows promising clinical results surpassing existing microsensor systems.
– Sava’s biosensor platform aims to expand beyond glucose tracking to detect additional molecules, offering versatile applications in various medical fields.
– Co-founders emphasize the potential of Sava’s technology to transform biosensing and personalized healthcare by providing a non-invasive, cost-effective solution for real-time health monitoring.
Tags: regulatory, drug delivery
Read more on drugdeliverybusiness.com